Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Encapsulation of hydroxyurea in exosomes derived from adipose mesenchymal stem cells enhances anticancer efficacy in breast cancer.

Taheri Kangarshahi Z., Ganji SM., Ashrafi F., Abbasi A.

Laboratory Study on Face & Skin, published in Transl Oncol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Transl Oncol (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41702234
PMCID
PMC12925517
DOI
10.1016/j.tranon.2026.102707

Abstract (original English)

Breast cancer treatment faces numerous challenges, including drug resistance and lack of precise drug targeting, which reduce therapeutic efficacy. This study investigated the potential use of hydroxyurea (HU), a potent antimetabolite, and exosomes derived from adipose-derived mesenchymal stem cells (AD-MSCs) as natural drug carriers to improve breast cancer therapy. Exosomes were isolated from AD-MSCs and characterized using immunophenotyping and various analytical techniques. HU was subsequently loaded into the exosomes via sonication, and its concentration was quantified by high-performance liquid chromatography (HPLC). Anticancer effects were evaluated through cell viability assays, apoptosis analysis, cell cycle profiling, and real-time PCR assessment of genes related to metastasis and angiogenesis. HU-loaded exosomes (HU-Exo) significantly enhanced cytotoxicity, reducing the IC50 value by up to threefold compared to free HU. HU-Exo also promoted apoptosis, induced S-phase cell cycle arrest, and inhibited migration of 4T1 breast cancer cells. Furthermore, expression of MMP2, MMP9, and VEGF was markedly downregulated. These results suggest that exosomes improve drug uptake and bypass drug resistance mechanisms, enabling dose reduction and minimizing side effects. This study introduces HU-Exo as a targeted and multifaceted drug delivery system capable of inhibiting breast tu

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research